BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

524 related articles for article (PubMed ID: 18300767)

  • 1. Antiangiogenic therapy in nonsmall cell lung cancer.
    Gutierrez M; Giaccone G
    Curr Opin Oncol; 2008 Mar; 20(2):176-82. PubMed ID: 18300767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The potential of antiangiogenic therapy in non-small cell lung cancer.
    Giaccone G
    Clin Cancer Res; 2007 Apr; 13(7):1961-70. PubMed ID: 17404076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antivascular agents for non-small-cell lung cancer: current status and future directions.
    Amir E; Mandoky L; Blackhall F; Thatcher N; Klepetko W; Ankersmit HJ; Reza Hoda MA; Ostoros G; Dank M; Dome B
    Expert Opin Investig Drugs; 2009 Nov; 18(11):1667-86. PubMed ID: 19877762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The emerging role of vascular endothelial growth factor receptor tyrosine kinase inhibitors.
    Langer CJ; Natale RB
    Semin Oncol; 2005 Dec; 32(6 Suppl 10):S23-9. PubMed ID: 16459176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New antiangiogenetic agents and non-small cell lung cancer.
    Gridelli C; Rossi A; Maione P
    Crit Rev Oncol Hematol; 2006 Oct; 60(1):76-86. PubMed ID: 16843002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beyond antiepidermal growth factor receptors and antiangiogenesis strategies for nonsmall cell lung cancer: exploring a new frontier.
    Sangha R; Lara PN; Mack PC; Gandara DR
    Curr Opin Oncol; 2009 Mar; 21(2):116-23. PubMed ID: 19532012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The actual place of anti-angiogenesis in non-small cell lung cancer].
    Mennecier B
    Rev Mal Respir; 2007 Oct; 24(8 Pt 2):6S198-205. PubMed ID: 18235414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting angiogenesis in lung cancer.
    Sandler AB
    Semin Oncol; 2005 Dec; 32(6 Suppl 10):S16-22. PubMed ID: 16459175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Angiogenesis and lung cancer].
    PĂ©rol M; Arpin D
    Bull Cancer; 2007 Jul; 94 Spec No():S220-31. PubMed ID: 17846008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the VEGF pathway: antiangiogenic strategies in the treatment of non-small cell lung cancer.
    Aita M; Fasola G; Defferrari C; Brianti A; Bello MG; Follador A; Sinaccio G; Pronzato P; Grossi F
    Crit Rev Oncol Hematol; 2008 Dec; 68(3):183-96. PubMed ID: 18606548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiogenesis inhibition in the treatment of lung cancer.
    Vokes E; Herbst R; Sandler A
    Clin Adv Hematol Oncol; 2006 Nov; 4(11 Suppl 23):1-10; quiz 11-2. PubMed ID: 17143257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting tumor neovasculature in non-small-cell lung cancer.
    Pallis AG; Syrigos KN
    Crit Rev Oncol Hematol; 2013 May; 86(2):130-42. PubMed ID: 23159217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New options for integrating antiangiogenic therapy and platinum-based first-line chemotherapy for advanced non-small-cell lung cancer.
    Manegold C
    Clin Lung Cancer; 2008; 9 Suppl 3():S100-8. PubMed ID: 19419923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined targeted therapies in non-small cell lung cancer: a winner strategy?
    Cascone T; Gridelli C; Ciardiello F
    Curr Opin Oncol; 2007 Mar; 19(2):98-102. PubMed ID: 17272980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiogenesis inhibitors in the treatment of small cell and non-small cell lung cancer.
    Blackhall FH; Shepherd FA
    Hematol Oncol Clin North Am; 2004 Oct; 18(5):1121-41, ix. PubMed ID: 15474338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical relevance of monoclonal antibodies in non small cell lung cancer.
    Filipits M
    J BUON; 2009 Sep; 14 Suppl 1():S147-52. PubMed ID: 19785057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multitargeted inhibitors in lung cancer: new clinical data.
    Bar J; Herbst RS; Onn A
    Clin Lung Cancer; 2008; 9 Suppl 3():S92-9. PubMed ID: 19419930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies.
    Grothey A; Ellis LM
    Cancer J; 2008; 14(3):170-7. PubMed ID: 18536556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-vascular endothelial growth factor monoclonals in non-small cell lung cancer.
    Sandler AB; Johnson DH; Herbst RS
    Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4258s-4262s. PubMed ID: 15217970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiangiogenic agents as second-line therapy for advanced non-small cell lung cancer.
    Reckamp KL
    Cancer Lett; 2012 Aug; 321(2):101-9. PubMed ID: 22306704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.